Biomedical subjects

Yasuhide Yamada

Publications and source records attributed to Yasuhide Yamada.

23 records · Page 2Linked to original sources

PubMed2002

Prognostic factors for patients with metastatic colorectal cancer receiving protracted venous infusion of 5-FU.

The objective of this study was to investigate the possible prognostic factors in patients with metastatic colorectal cancer (CRC) treated with protracted venous infusion (PVI) of 5-fluorouracil (5-FU). PVI of 5-FU is considered to be one of the standard therapies for patients with CRC because of its high efficacy and low toxicity, but possible prognostic factors in patients with CRC treated with PVI of 5-FU have not been reported until now. One hundred two consecutive patients with metastatic CRC, treated with PVI of 250 mg/m(2) /d of 5-FU at the National Cancer Center Hospital between January 1991 and December 1998, were investigated retrospectively. The data were evaluated for possible correlations with clinicopathologic indices or prognosis. In this study, grade III nausea, stomatitis, diarrhea, and hand-foot syndrome occurred in only 3%, 5%, 5%, and 6% of cases, respectively. No grade III or more hematologic toxicities were observed. The overall response (complete response + partial response) rate for all 102 cases was 26%, with a 95% CI of 18% to 35%. Overall median survival time for the 102 cases was 303 days. In multivariate analysis, the favorable prognostic factors were normal albumin level (<or=3.7 g/dl), histologic grades I, II, and low carcinoembryonic antigen level (<100 ng/ml).

Aged↗

PubMed2002

Three novel single nucleotide polymorphisms in UGT1A10.

Three novel single nucleotide polymorphisms (SNPs) were found in the UDP-glucuronosyltransferase (UGT) 1A10 gene from 24 Japanese patients with various cancers who were administered the anti-tumor drug, irinotecan (CPT-11). The detected SNPs were as follows: 1) SNP, MPJ6_U1A003; GENE NAME, UGT1A10; ACCESSION NUMBER, AF297093; LENGTH, 25 bases; 5'-CAGATGCCATGAC/TTTTCAAGGAGAG-3'. 2) SNP, MPJ6_U1A004; GENE NAME, UGT1A10; ACCESSION NUMBER, AF297093; LENGTH, 25 bases; 5'-CCTAGAAATAGCC/TTCTGAAATTCTC-3'. 3) SNP, MPJ6_U1A030; GENE NAME, UGT1A10; ACCESSION NUMBER, AF297093; LENGTH, 25 bases; 5'-GGTTGTAGTCATG/ACCAGAGGTGAGT-3' All the three SNPs were located in exon 1 and their frequencies were all 0.021. Among these SNPs, MPJ6_U1A003 and U1A030 resulted in amino acid alterations, T202I and M59I, respectively. The third SNP, MPJ6_U1A004, introduced a synonymous amino acid change (A231A).

Journal Article↗

PubMedDate not supplied

Long-term survivor of gastric small cell carcinoma.

We describe the long-term survival of a patient following the diagnosis of primary gastric small cell carcinoma. In January 2000, a 73-year-old male was found to have advanced gastric small cell carcinoma directly invading his liver. He received combination chemotherapy with cisplatin and irinotecan as first-line chemotherapy, then cisplatin and etoposide as second-line chemotherapy. He had a complete response after four cycles of second-line chemotherapy. In March 2001, the tumor recurred in the stomach and the patient underwent a total gastrectomy. He has survived free of disease for more than 2 years after the first diagnosis.

Aged↗

PubMedDate not supplied

Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.

BACKGROUND: A highly specific antibody against recombinant human dihydropyrimidine dehydrogenase (DPD) has been developed to immunohistochemically assess DPD expression in tumors. A new oral DPD inhibitory fluoropyrimidine (DIF), S-1, is reportedly effective against gastric scirrhous carcinoma. PATIENTS AND METHODS: In this study, the relationship between immunoreactivity to DPD in biopsy specimens and the effects of chemotherapy were investigated in 61 patients treated with first-line fluoropyrimidine-based chemotherapy (S-1:DIF, 5-FU:non-DIF) for gastric scirrhous carcinoma. RESULTS: The response rate was significantly higher in patients with DPD-positive tumors than in those with DPD-negative tumors in the S-1 group (45.5%, 10.0%: p < 0.05), as compared to the 5-FU group (0%, 5.6%: p = 0.398). According to the median survival time, there was no significant difference between patients with DPD-positive tumors (364 days) and those with DPD-negative tumors (406 days; p = 0.626) in either the S-1 group or the 5-FU group (181 days and 256 days, respectively; p = 0.543). CONCLUSION: This study indicates that S-1 may be effective even in gastric scirrhous carcinoma with a high level of DPD activity.

Adenocarcinoma, Scirrhous↗

PubMedDate not supplied

Small cell carcinoma of the esophagus. Analysis of 14 cases and literature review.

BACKGROUND/AIMS: The aims of this study are to retrospectively analyze data on the epidemiology, clinical characteristics, and treatment outcomes of 14 cases of small cell carcinoma of the esophagus. METHODOLOGY: Patient records were reviewed for data on demographics, presenting symptoms, diagnosis, disease stage, type of treatment and outcome. RESULTS: Between January 1990 and December 2001, 14 patients with small cell carcinoma of the esophagus were treated at the National Cancer Center Hospital, representing 0.8% of all esophageal carcinomas diagnosed during this period. Eleven patients presented with extensive disease at the time of diagnosis, while three patients were noted to have limited disease. Nine patients received combination chemotherapy with or without radiotherapy. Three of these patients achieved a complete response to first-line treatment and two of them have survived more than two years. Five patients underwent esophagectomy as an initial treatment with curative intent. All of these patients developed early relapse after esophagectomy, and only one patient has survived more than two years. The overall median survival was 7.7 months (range: 0.6-89.1 months) for all 14 patients. CONCLUSIONS: Although curative esophagectomy may be effective as a primary treatment in some patients, systemic chemotherapy with or without concurrent radiotherapy should be considered as an important treatment option for small cell carcinoma of the esophagus.

Adult↗